Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMYDA-9 Dapagliflozin
2025-521481-10-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Infarct size by cardiac MRI at 3 months. Planned start Aug 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2025-521481-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521481-10-00.